LAVAL, QC, May 30 /PRNewswire-FirstCall/ -- Labopharm Inc. (TSX: DDS, NASDAQ:DDSS) today announced that James R. Howard-Tripp, President and Chief Executive Officer of the Company, will speak at the Canaccord Adams Life Sciences Conference at the University Club in Montreal on Wednesday, May 31, 2006 at 12:15 p.m. (ET).
Interested parties may access the live webcast by visiting the "Latest Webcasts" section of the homepage at http://www.labopharm.com/. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast. An audio archive of the presentation will be available until June 30, 2006.
About Labopharm Inc.
Labopharm Inc. (TSX: DDS, NASDAQ:DDSS) is an international, specialty pharmaceutical company focused on the development of drugs incorporating Contramid(R), the Company's proprietary advanced controlled-release technology. Labopharm's lead product, a once-daily formulation of the analgesic tramadol, is marketed in Germany and has received regulatory approval in 21 other European countries. In the U.S., the Company's NDA for once-daily tramadol is under review at the FDA and the Company has secured a licensing and distribution agreement with Purdue Pharma, a premier marketer of long-acting pain medications. The Company's pipeline includes a combination of proprietary and partnered programs with products both in clinical trials and in preclinical development. For more information, please visit http://www.labopharm.com/.
This press release contains forward-looking statements, which reflect the Corporation's current expectations regarding future events. The forward- looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the successful and timely completion of clinical studies, the uncertainties related to the regulatory process and the commercialization of the drug thereafter. Investors should consult the Corporation's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Corporation disclaims any obligation to update these forward-looking statements.
